21 completed, 16 recruiting, 13 unknown, 5 terminated. 29 Phase 1, 17 Phase 2, 16 Not applicable, 2 Early Phase 1.
Follow Tumor, Solid: new trials by email Literature Review of Tumor, Solid trials Research Report on Tumor, Solid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors Collection of data from the patient's medical file. - Tumor, Solid, Neuroblastic Tumors | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 150 | 2025-10-01 | 2025-09-12 | |
| Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors RGL-270 Injection, Adebelimab Injection - Tumor, Solid | Phase 1 | Recruiting | Xian-Jun Yu | 198 | 2025-09-07 | 2026-01-16 |
| NW-301 TCR-T in Patients With Advanced Solid Tumor NW-301V, Drug: NW-301D - Tumor, Solid | Phase 1 | Not yet recruiting | Peking University | 44 | 2025-05-10 | 2025-05-04 |
| A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment XNW29016 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 132 | 2025-04-11 | 2026-10-16 |
| AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors AD1208 - Solid Tumor, Adult, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Avelos Therapeutics Inc. | 36 | 2025-03-11 | 2025-04-04 |
| Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron - Tumor, Solid, Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan Enray Pharmaceutical Sciences Company | 54 | 2024-11-12 | 2026-02-25 |
| Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) Proton Radiation Therapy - Tumor, Solid | Not applicable | Completed | Varian, a Siemens Healthineers Company | 47 | 2024-09-05 | 2025-12-15 |
| TumorGlow Intraoperative Molecular Imaging (IMI) Indocyanine Green - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | University of Pennsylvania | 500 | 2024-08-14 | 2026-03-09 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Recruiting | Tao Zhang | 9 | 2024-06-19 | 2025-07-31 |
| A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors tumor neoantigen specific T cell - Tumor, Solid | Early Phase 1 | Unknown | JIANG LONGWEI | 6 | 2024-04-18 | 2024-05-28 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Recruiting | Ting Deng | 9 | 2024-04-08 | 2025-11-25 |
| Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery Radiotherapy in painting dose on histoscannographic mapping, Standard pan-sinusal Radiotherapy - Tumor, Solid | Phase 2 | Recruiting | Centre Francois Baclesse | 52 | 2024-03-11 | 2026-07-02 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Active not recruiting | TingBo Liang | 18 | 2024-02-01 | 2026-10-15 |
| The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) HistoSonics Edison System - Renal Cancer, Tumor, Solid | Not applicable | Active not recruiting | HistoSonics, Inc. | 67 | 2024-01-04 | 2026-06-23 |
| PET Imaging of 68Ga-NOTA-H006 in Malignancy 68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg. - Tumor, Solid | Not applicable | Not yet recruiting | YiHui Guan | 15 | 2023-12-01 | 2023-12-08 |
| Autologous TLPO Vaccine Basket Tumor lysate, particle only (TLPO) vaccine - Tumor, Solid, Tumor Metastasis | Phase 2 | Terminated | Elios Therapeutics, LLC | 63 | 2023-11-29 | 2025-09-15 |
| LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. LEU011 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Leucid Bio | 17 | 2023-11-13 | 2026-08-31 |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents OR502, Cemiplimab - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | OncoResponse, Inc. | 168 | 2023-10-24 | 2025-01-07 |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. ONM-501, Cemiplimab - Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | OncoNano Medicine, Inc. | 168 | 2023-10-13 | 2025-12-24 |
| 18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor Radiation: 18F-AlF-FAPi-04, Radiation: 18F-FDG - Tumor, Solid | Early Phase 1 | Unknown | Affiliated Hospital of North Sichuan Medical College | 60 | 2023-07-18 | 2023-11-13 |
Showing 20 of 63. Sign in to see all of them.
Neoplasms (63) · Neoplasm Metastasis (11) · Colorectal Neoplasms (5) · Melanoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Pancreatic Neoplasms (4) · Disease (3) · Lymphoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Renal Cell (2) · Hematologic Neoplasms (2)
Neoplasms by Site (18) · Pathological Conditions, Signs and Symptoms (15) · Pathologic Processes (13) · Neoplasms by Histologic Type (12) · Neoplastic Processes (11) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Neoplasms, Glandular and Epithelial (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Gastrointestinal Diseases (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Nerve Tissue (7)
pembrolizumab (6) · BDB001 (3) · cemiplimab (3) · ulixertinib (2) · Docetaxel (1) · Hematologic Tests (1) · Hydrocortisone (1) · Hydroxychloroquine (1) · Indocyanine Green (1) · Injections (1) · MK-8353 (1) · Proton Pump Inhibitors (1) · Proton Therapy (1) · Radiotherapy (1) · Restraint, Physical (1)
Eikon Therapeutics (4) · Varian, a Siemens Healthineers Company (4) · The First Affiliated Hospital of Xiamen University (3) · Aadi Bioscience, Inc. (2) · HistoSonics, Inc. (2) · OncoResponse, Inc. (2) · Peking University Cancer Hospital & Institute (2) · AVM Biotechnology Inc (1) · Affiliated Hospital of North Sichuan Medical College (1) · Andes Biotechnologies (1) · Assistance Publique - Hôpitaux de Paris (1) · Avelos Therapeutics Inc. (1) · BioMed Valley Discoveries, Inc (1) · Biorek S.R.L. (1) · Centre Francois Baclesse (1)
United States (25) · China (24) · France (3) · United Kingdom (3) · Israel (2) · Italy (2) · South Korea (2) · Spain (2) · Australia (1) · Belgium (1) · Chile (1) · Germany (1) · Poland (1) · Puerto Rico (1)
Harry Raftopoulos, MD (4) · Long Sun, PhD (2) · Alberto Pappo, MD (1) · Aurelie Garant, MD (1) · Bernadita Mendez, PhD (1) · Brock C Christensen, PhD (1) · Bryan Bednarz, PhD (1) · Daniel Chang, MD (1) · Edward Loniewski, D.O. (1) · Fang Li, MD (1) · Fang Xie, PhD (1) · Francesco Montorsi (1) · Gabriele Anania (1) · Hongyan Zhang (1)
PMID 10749239, PMID 14602860, PMID 19682776, PMID 22535923, PMID 25143865, PMID 25422273, PMID 25441588, PMID 25684695, PMID 25752883, PMID 26853397, PMID 27637832, PMID 29467321, PMID 29496096, PMID 29626119, PMID 30896609, PMID 31631858, PMID 31912902, PMID 32222810, PMID 32366995, PMID 32632460, PMID 33179149, PMID 33320857, PMID 34145597, PMID 34490992, PMID 34581274, PMID 35040171, PMID 37385675, PMID 38331453, PMID 38782454, PMID 39443386, PMID 40774265, PMID 42637259
R01CA190298 (1)